Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Adagio Medical Holdings, Inc Common Stock (ADGM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ADGM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50.85% | Avg. Invested days 33 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.77M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.04 | 52 Weeks Range 0.62 - 9.34 | Updated Date 06/16/2025 |
52 Weeks Range 0.62 - 9.34 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5822.92% |
Management Effectiveness
Return on Assets (TTM) -82.76% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22385905 | Price to Sales(TTM) 29.11 |
Enterprise Value 22385905 | Price to Sales(TTM) 29.11 | ||
Enterprise Value to Revenue 370.25 | Enterprise Value to EBITDA - | Shares Outstanding 15381600 | Shares Floating 3170756 |
Shares Outstanding 15381600 | Shares Floating 3170756 | ||
Percent Insiders 0.29 | Percent Institutions 85.46 |
Upturn AI SWOT
Adagio Medical Holdings, Inc Common Stock
Company Overview
History and Background
Adagio Medical is a medical technology company focused on developing and commercializing innovative cryoablation technologies for the treatment of atrial fibrillation (Afib). Founded in 2011, Adagio Medical aims to provide more effective and durable solutions for patients with cardiac arrhythmias.
Core Business Areas
- Cryoablation Technology: Develops and manufactures cryoablation systems and catheters used to treat atrial fibrillation by freezing heart tissue to create lesions and block abnormal electrical signals.
Leadership and Structure
The leadership team consists of experienced professionals in the medical device industry. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and clinical affairs.
Top Products and Market Share
Key Offerings
- iCLAS Integrated Cryoablation System: A single catheter solution for both pulmonary vein isolation (PVI) and left atrial posterior wall ablation. Market share is growing, but specific figures are not publicly available. Competitors include Medtronic, Boston Scientific, and Abbott in the cardiac ablation market.
- Cryo Console: The generator for the iCLAS Integrated Cryoablation System. This console delivers energy to the cryocatheter and controls the ablation process. Competitors include Medtronic, Boston Scientific, and Abbott.
Market Dynamics
Industry Overview
The cardiac ablation market is growing due to the increasing prevalence of atrial fibrillation and advancements in ablation technologies. Key trends include the development of more effective and less invasive ablation procedures.
Positioning
Adagio Medical is positioned as an innovator in the cryoablation market, offering a unique single-catheter solution. Its competitive advantage lies in its integrated cryoablation technology.
Total Addressable Market (TAM)
The global cardiac ablation market is projected to reach over $10 billion. Adagio Medical aims to capture a significant share of this market through its innovative cryoablation systems.
Upturn SWOT Analysis
Strengths
- Innovative cryoablation technology
- Single-catheter solution
- Experienced leadership team
- Strong clinical data supporting efficacy
Weaknesses
- Limited market presence compared to larger competitors
- Dependence on a single product line
- Relatively small company size may limit resources
- Not profitable yet
Opportunities
- Expanding into new markets
- Developing new applications for cryoablation technology
- Forming strategic partnerships with hospitals and cardiology centers
- Increasing awareness of the benefits of cryoablation
Threats
- Competition from established medical device companies
- Regulatory hurdles and reimbursement challenges
- Technological advancements in competing ablation modalities
- Economic downturn impacting hospital capital expenditures
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
Competitive Landscape
Adagio Medical's advantage is its innovative technology. However, it faces strong competition from larger companies with greater resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been reliant on product adoption in early markets.
Future Projections: Future growth projections are unavailable. Growth is dependent on commercial success and market penetration.
Recent Initiatives: Recent initiatives include expansion into new geographic markets and ongoing clinical trials to demonstrate the safety and efficacy of its cryoablation system.
Summary
Adagio Medical is a promising medical device company with innovative cryoablation technology. While they operate in a competitive market dominated by larger players, their unique single-catheter solution offers a competitive advantage. However, challenges remain, including market penetration and obtaining regulatory approvals. Adagio Medical needs to focus on expanding its market reach and demonstrating clinical superiority to capitalize on its technology.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Analyst Estimates
- Press Releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adagio Medical Holdings, Inc Common Stock
Exchange NASDAQ | Headquaters Laguna Hills, CA, United States | ||
IPO Launch date 2024-08-01 | CEO & Director Mr. Todd Usen | ||
Sector Healthcare | Industry Medical Devices | Full time employees 80 | Website https://adagiomedical.com |
Full time employees 80 | Website https://adagiomedical.com | ||
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.